Filing Flows

Filing Flows › Seres Therapeutics (MCRB) › Next earnings date

Seres Therapeutics (MCRB) earnings: missed the estimate

Seres Therapeutics (MCRB) reported on Nov 4, 2026 and missed the EPS estimate: −$1.63 against −$1.00 (-62.2%). Revenue was $593K for Q3 2026, +69% year over year. It beat the EPS estimate in 20% of the quarters on record.

Last result−62.2% vs estimate
Beat rate20%

The last report

Seres Therapeutics reported revenue of $593K for the third quarter 2026 (+69% Y/Y), net loss $16.3M. How it makes money → · Every quarter →

Seres Therapeutics: EPS against the estimate, last 5 reportsSeres Therapeutics: EPS against the estimate, last 5 reportsEstimateReported$1.28$0.94Nov 25−$1.60−$1.76Mar 26−$1.88−$2.08May 26−$2.19$1.07Aug 26−$1.00−$1.63Nov 26
Latest (Nov 26): Estimate −$1.00, Reported −$1.63.

Seres Therapeutics' latest quarter

Seres Therapeutics, Q3 2026: revenue $593K (+69% year over year), net loss $16.3M, operating cash flow −$10.5M. The chart follows the revenue to costs, profit and cash.

Questions

Did Seres Therapeutics beat earnings?

Seres Therapeutics (MCRB) reported on Nov 4, 2026 and missed the EPS estimate: −$1.63 against −$1.00 (-62.2%).

When does MCRB report earnings?

The next date is not set yet.

Does Seres Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 20% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.